Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 516 • 2019 ACR/ARP Annual Meeting
Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib
Michael Weinblatt¹, Eduardo Mysler ², Andrew Östör ³, Aaron Broadwell ⁴, Slawomir Jeka ⁵, Kendall Dunlap ⁶, Jessica Suboticki ⁶, Jose Jeffrey Enejosa ⁶, Barbara Hendrickson ⁶, Sheng Zhong ⁶, Katya Cherny ⁶ and Grace Wright ⁷, ¹Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ²Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ³Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ⁴Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ⁵University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁷New York University Langone Medical Center, New York, NY, USA, New York
Background/Purpose: Upadacitinib (UPA), an oral selective JAK1 inhibitor, has demonstrated favorable efficacy and acceptable safety in five Phase 3 global studies in patients with moderately…
Abstract Number: 815 • 2019 ACR/ARP Annual Meeting
Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis
Koji Fukuda¹, Yasushi Miura ², Shinya Hayashi ¹, Toshihisa Maeda ³ and Ryosuke Kuroda ¹, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Division of Orthopedic Science, Department Of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Fas ligand (FasL) is a member of tumor necrosis factor superfamily (TNFSF6) and reported to contribute to synovial hyperplasia of rheumatoid arthritis (RA). Apoptosis…
Abstract Number: 925 • 2019 ACR/ARP Annual Meeting
Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database
Sebastian E. Sattui¹, Mangala Rajan ², Sarah Lieber ¹, Geyanne Lui ³, Jeffrey Curtis ⁴, Lisa Mandl ⁵ and Iris Navarro-Millan ², ¹Hospital for Special Surgery, New York, ²Weill Cornell Medicine, New York, ³Weill-Cornell Medicine, New York, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Inflammation has been thought to be a risk factor for cognitive impairment and dementia. RA, an autoimmune inflammatory disorder is associated with a high…
Abstract Number: 1132 • 2019 ACR/ARP Annual Meeting
Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ², Hiren Verma ³ and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI, ³Brown University School of Public Health, Providence, RI
Background/Purpose: Biologic disease modifying agents (DMARDs) are an integral part of rheumatoid arthritis (RA) treatment, but the adoption of infusion-based products has not been reported.…
Abstract Number: 1334 • 2019 ACR/ARP Annual Meeting
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Dalifer Freites Nuñez¹, Leticia León ², Marta Redondo ³, Cristina Vadillo Font ⁴, Pia Lois ⁵, Arkaitz Mucientes Ruiz ⁴, Luis Rodríguez-Rodríguez ⁶, Benjamín Fernández Gutiérrez ⁷, Juan Angel Jover Jover ⁴ and lydia Abasolo Alcazar ⁴, ¹Hospital Clínico San Carlos, MADRID, Spain, ²Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ³Universidad Camilo José Ceja, Madrid, Madrid, Spain, ⁴HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Fundación para la Investigación Biomedica, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid
Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue…
Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Jatin Mistry ¹, Margaret Sibley ², Catherine Smith ³, Malama Sumbwanyambe ² and Patrick Kiely², ¹St George's University of London, London, United Kingdom, ²St George's University Hospitals NHS Trust, London, United Kingdom, ³St Georges University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…
Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Jeffrey Curtis¹, Daniel Aletaha ², Gerd Burmester ³, Kerri Ford ⁴, Hubert van Hoogstraten ⁵, Henry Leher ⁶, Karthinathan Thangavelu ⁷ and Vivian Bykerk ⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of Vienna, Vienna, Austria, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁷Sanofi Genzyme, Boston, MA, ⁸Hospital for Special Surgery, New York City, NY
Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…
Abstract Number: 1421 • 2019 ACR/ARP Annual Meeting
Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results
Florencia Pierini¹, Ignacio Gandino ¹, Eliana Botta ², Fernando Brites ², Tomas Meroño ², Osvaldo Luis Cerda ³, Gustavo Citera ⁴, Javier Rosa ⁵, Patricia Sorroche ⁶, Laura Boero ², Maximiliano Martin ², Soledad saez ⁶, Walter Tetzlaff ² and Enrique Soriano ⁷, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Capital Federal, Argentina, ²Universidad de Buenos Aires, Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: In patients with Rheumatoid Arthritis (RA), qualitative alterations of low and high density lipoproteins (LDL and HDL, respectively) might partially explain their increased cardiovascular…
Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Marianne Kerski¹, Peter Boersma ², Eric Miller ³, Ashley Brenner ⁴, Genevieve Melton ⁵ and Anna Shmagel ⁶, ¹University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota School of Public Health, Minneapolis, ³University of Minnesota, Woodbury, MN, ⁴University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, ⁵University of Minnesota Department of Surgery, Minneapolis, MN, ⁶University of Minnesota, Minneapolis, MN
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
Abstract Number: 1938 • 2019 ACR/ARP Annual Meeting
The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study
Amogh Pathi ¹, Mette Smed ², Lior Pachter ³, Elizabeth Purdom ⁴, Matthew Wright ⁵, Nicholas Jewell ⁴, J. Lee Nelson ⁶, Jørn Olsen ⁷, Merete Lund Hetland ⁸, Vibeke Zoffmann ⁹ and Damini Jawaheer¹⁰, ¹UCSF Benioff Children's Hospital Oakland, Oakland, ²Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Caltech, Pasadena, ⁴University of California Berkeley, Berkeley, ⁵UCSF Benioff Children's Hopsital Oakland, Oakland, ⁶Fred Hutchinson Cancer Research Center, Seattle, ⁷Aarhus University Hospital, Aarhus, Denmark, ⁸DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁹Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, ¹⁰UCSF Benioff Children's Hospital Oakland, Oakland, CA
Background/Purpose: Pregnancy is known to induce a natural improvement of Rheumatoid Arthritis (RA) symptoms in 50-75% of patients as gestation progresses. However, the underlying mechanisms…
Abstract Number: 2091 • 2019 ACR/ARP Annual Meeting
The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients
Mariana Useche ¹, Ramanakumar Agnihotram ¹, Sasha Bernatsky ², Brian Ward ³ and Ines Colmegna³, ¹The Research Institute of the McGill University Health Center, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Center, Montreal, QC, Canada
Background/Purpose: The high dose trivalent inactivated influenza vaccine (HD-TIV) contains four times the antigen dose per strain of the standard-dose inactivated influenza vaccines. HD-TIV is…
Abstract Number: 2258 • 2019 ACR/ARP Annual Meeting
Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis
Sandra Pelaez ¹, Vincent Gosselin Boucher ², Valeria Valerio ³, Elizabeth M. Hazel ⁴, Kim Lavoie ⁵, Brian Ward ⁶ and Ines Colmegna⁶, ¹Research Centre of the Sainte-Justine University Hospital, Montreal, Canada, ²Montreal Behavioural Medicine Centre, Centre Intégré Universitaire de santé et services sociaux du Nord-de-l’Ile-de-Montréal (CIUSSS-NIM), Hôpital du Sacré-Cœur de Montréal & Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, Canada, ⁵Montreal Behavioural Medicine Centre, Centre Intégré Universitaire de santé et services sociaux du Nord-de-l’Ile-de-Montréal (CIUSSS-NIM), Hôpital du Sacré-Cœur de Montréal & Department of Psychology, Université du Québec à Montréal, Montreal, Canada, ⁶McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Vaccine hesitancy -the reluctance or refusal to vaccinate despite the availability of vaccines- is one of the threats to global health set by the…
Abstract Number: 2314 • 2019 ACR/ARP Annual Meeting
Improved Anxiety, Depression, and Emotional Distress for Rheumatoid Arthritis Patients Following the Completion of an Online Mental Health Intervention
Caitlin Blaney¹, Carol Hitchon ¹, Ruth Ann Marrie ², Corey Mackenzie ¹, Pamela Holens ¹ and Renée El-Gabalawy ², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Background: Anxiety and depression are common in people with rheumatoid arthritis (RA). These comorbidities are associated with worse disease outcomes including pain and functional…
Abstract Number: 2332 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients
Hafis Muhammed¹, Durga P Misra ¹, Sujata Ganguly ¹, Sarit Sekhar Pattanaik ¹, Saurabh Chaturvedi ¹, Harshit Singh ¹, Mohit K Rai ¹, Anamika Anuja ¹, Namita Mohindra ¹, Neeraj Jain ¹, Sudeep Kumar ¹ and Vikas Agarwal ¹, ¹SGPGI, Lucknow, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis(RA) patients have increased cardiovascular(CV) risk with no data on CV risk scores in Indian patients.The primary objective was to study prevalence of…
Abstract Number: 2356 • 2019 ACR/ARP Annual Meeting
Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Thao Nguyen¹, Gia Deyab ², Morten Fagerland ³, Stefan Agewall ³, Gro Eilertsen ⁴, Mark Feinberg ⁵, Knut Mikkelsen ⁶, Øystein Førre ³ and Ivana Hollan ⁷, ¹Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Innlandet Hospital Trust, Bærum, Akershus, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴The Artic University of Norway, Tromsø, Norway, ⁵Harvard Medical School and Brigham and Women´s Hospital, Boston, Boston, MA, ⁶Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Oppland, Norway, ⁷Lillehammer Hospital for Rheumatic Diseases and Brigham and Women’s Hospital, Boston, Lillehammer, Oppland, Norway
Background/Purpose: Patients with rheumatoid arthritis (RA) are predisposed to impaired cardiac function and heart failure (HF). While the pathophysiology has not been fully elucidated yet,…

« Previous Page
1
…
6
7
8
9
10
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].